Protein kinase is an enzyme that shuffles protein structure by transferring phosphate collected from ATP(Adenosine Triphosphate) . Protein kinase help in regulating variety of cell functions such as cell cycle, cell differentiation, cell proliferation and apoptosis. These cell processes are used in regulating various cell activities in cancer. The global inhibitors market was valued at approximately $105 billion. Increase in incident of cancer diseases is driving the growth for kinase inhibitor market. According to American Cancer Society, there were more than 1,660,290 new cases diagnosed in 2013. This shows potential for kinase inhibitors in cancer therapies. The growth of kinase inhibitor market is hindered by cost of treatment and lack of funds in conducting research. For Example, the cost of TKI (Tyrosin kinase inhibitors) was approximately $26,400 in non-pharmaceutical spending in 2012

Increase in clinical trials for commercialization of kinase inhibitors in cancer treatment is facing challenges due to strict government regulations. However, an increase in investment from pharmaceutical companies is promoting the growth for kinase inhibitor market. This report provides an in depth analysis of clinical development and reimbursement strategies adopted by respective governments. 

Key companies include in the report are Bristol-Myers Squibb, Boehringer Ingelheim, Cytrx Corporation, Eisai Inc. Eton Bioscience Inc., Glaxosmithkline, Merck Serono Sa, Novartis International Ag, Osi Pharmaceuticals Llc, Pfizer.

KEY BENEFITS

• The report provides key developmental strategies adopted by top market players engaged in this business so that companies involved in development kinase inhibitors market can get competitive intelligence of their competitors
• The report focuses on market estimation for types of kinase inhibitors and geographic segments are derived from current market scenario and expected market trends that are forecasted
• Competitive landscape and competitor strategy analysis would help in better planning and execution of business strategies 
• SWOT analysis and strategic developments included in the report for key market players are included in the report to get better understanding of potential opportunities and challenges for companies
• Impact analysis of top 10 factors to provide market situation to top management of surgical equipment market.

KEY MARKET SEGMENTS

BY TYPES

• Tyrosin kinase inhibitors (TKI)
• Receptor Tyrosine Kinase Inhibitors
  • EGFR
  • PDGFR
  • VEGFR
  • HER2
• Non-Receptor Tyrosine Kinase Inhibitors
  • BCR-ABL
  • Janus Kinase (JAK) Inhibitor
  • Mesenchymal Epithelial Transition Growth Factor (c-MET)
  • Spleen Tyrosine Kinase (SYK) Inhibitors
• Mulikinase inhibitors
• Threonine kinase inhibitor
• mTOR Kinase Inhibitors
• B RAF
• RHO Kinase Inhibitors
• Cyclin Dependant Kinase Inhibitor
• Aurora Kinase Inhibitors
• MAP/MEK Kinase Inhibitors
• JNK Inhibitors
• Protein Kinase C Inhibitors
• PI3K Inhibitors
• Others (Monoclonal  antibody kinase inhibitor)
• Humanized monoclonal antibody
• Chimeric monoclonal antibody
• Human monoclonal antibody

BY GEOGRAPHY 

• North America
• Europe
• Asia-Pacific
• RoW

KEY AUDIENCES

• Pharmaceutical companies
• Private and Government research institutes
• Academic Institutes
• Healthcare facilities